Loring Wolcott & Coolidge Fiduciary Advisors LLP Repligen Corp Transaction History

Loring Wolcott & Coolidge Fiduciary Advisors LLP

$10.9 Billion
Q4 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$162.42 - $220.56 $5,522 - $7,499	34 New	34 $6,000
Q4 2021 Feb 14, 2022	SELL	$247.59 - $304.47 $2,971 - $3,653	-12 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$194.77 - $324.21 $2,726 - $4,538	-14 Reduced 53.85%	12 $3,000
Q2 2021 Aug 13, 2021	BUY	$165.87 - $220.95 $4,312 - $5,744	26 New	26 $5,000

Others Institutions Holding RGEN

# of Institutions

480

Shares Held

54.3M

Call Options Held

341K

Put Options Held

235K

Black Rock Inc. New York, NY

7.57M
Shares

$1.28 Billion
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

6.39M
Shares

$1.08 Billion
0.11% of portfolio
Vanguard Group Inc Valley Forge, PA

5.04M
Shares

$855 Million
0.01% of portfolio
State Street Corp Boston, MA

1.62M
Shares

$275 Million
0.01% of portfolio
Champlain Investment Partners, LLC Burlington, VT

1.42M
Shares

$241 Million
1.34% of portfolio

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $9.4B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.

Account